alexa Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial.


Journal of Addiction Research & Therapy

Author(s): Levin FR, Mariani JJ, Specker S, Mooney M, Mahony A,

Abstract Share this page

Abstract IMPORTANCE: Adult attention-deficit/hyperactivity disorder (ADHD) is prevalent but often unrecognized, in part because it tends to co-occur with other disorders such as substance use disorders. Cocaine use disorder is one such disorder with high co-occurrence of ADHD. OBJECTIVE: To examine whether treatment of co-occurring ADHD and cocaine use disorder with extended-release mixed amphetamine salts is effective at both improving ADHD symptoms and reducing cocaine use. DESIGN, SETTING, AND PARTICIPANTS: Thirteen-week, randomized, double-blind, 3-arm, placebo-controlled trial of participants meeting DSM-IV-TR criteria for both ADHD and cocaine use disorder conducted between December 1, 2007, and April 15, 2013, at 2 academic health center substance abuse treatment research sites. One hundred twenty-six adults diagnosed as having comorbid ADHD and cocaine use disorder were randomized to extended-release mixed amphetamine salts or placebo. Analysis was by intent-to-treat population. INTERVENTIONS: Participants received extended-release mixed amphetamine salts (60 or 80 mg) or placebo daily for 13 weeks and participated in weekly individual cognitive behavioral therapy. MAIN OUTCOMES AND MEASURES: For ADHD, percentage of participants achieving at least a 30\% reduction in ADHD symptom severity, measured by the Adult ADHD Investigator Symptom Rating Scale; for cocaine use, cocaine-negative weeks (by self-report of no cocaine use and weekly benzoylecgonine urine screens) during maintenance medication (weeks 2-13) and percentage of participants achieving abstinence for the last 3 weeks. RESULTS: More patients achieved at least a 30\% reduction in ADHD symptom severity in the medication groups (60 mg: 30 of 40 participants [75.0\%]; odds ratio [OR] = 5.23; 95\% CI, 1.98-13.85; P < .001; and 80 mg: 25 of 43 participants [58.1\%]; OR = 2.27; 95\% CI, 0.94-5.49; P = .07) compared with placebo (17 of 43 participants [39.5\%]). The odds of a cocaine-negative week were higher in the 80-mg group (OR = 5.46; 95\% CI, 2.25-13.27; P < .001) and 60-mg group (OR = 2.92; 95\% CI, 1.15-7.42; P = .02) compared with placebo. Rates of continuous abstinence in the last 3 weeks were greater for the medication groups than the placebo group: 30.2\% for the 80-mg group (OR = 11.87; 95\% CI, 2.25-62.62; P = .004) and 17.5\% for the 60-mg group (OR = 5.85; 95\% CI, 1.04-33.04; P = .04) vs 7.0\% for placebo. CONCLUSIONS AND RELEVANCE: Extended-release mixed amphetamine salts in robust doses along with cognitive behavioral therapy are effective for treatment of co-occurring ADHD and cocaine use disorder, both improving ADHD symptoms and reducing cocaine use. The data suggest the importance of screening and treatment of ADHD in adults presenting with cocaine use disorder. TRIAL REGISTRATION: Identifier:NCT00553319.
This article was published in JAMA Psychiatry and referenced in Journal of Addiction Research & Therapy

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version